Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This paper reviews the complex pathophysiology of polycystic ovary syndrome, exploring how hormonal and metabolic disturbances contribute to its symptoms and related health risks, but it presents no new findings.

This study found that combining low-dose spironolactone with metformin provided greater clinical benefits and improved treatment compliance in women with PCOS compared to either drug alone.

This study found that procyanidin B-2 may promote hair growth by reducing expression and inhibiting translocation of PKC isozymes in murine hair epithelial cells.

This study reported that Ell-Cranell® alpha 0.025% solution significantly increased hair counts and diameter in Korean women with female pattern hair loss over an 8-month period, showing both efficacy and safety.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

This study found that the orally disintegrating tablet and standard tablet formulations of finasteride met bioequivalence criteria in fasting healthy adult male Han Chinese volunteers, although there was a significant difference in time to maximum concentration.

This study found that valproate sustained-release monotherapy provided effective short-term seizure control and was well tolerated in newly-diagnosed epileptic patients with partial seizures in the Gulf Cooperation Council countries.

This study reported that more sensitive, early diagnosis and treatment of COVID-19 with drug combinations significantly improved clinical outcomes in males with or without androgenetic alopecia, preventing severe progression.

This study found that intradermal administration of QR678 Neo® significantly reduced hair fall and improved hair growth in patients with androgenetic alopecia and female pattern hair loss, with no side effects reported during long-term follow-up.

This study found that SESA oil significantly improved hair and scalp ailments more than coconut oil, with no adverse reactions reported during the study period.

In this study, ritlecitinib 50-mg showed clinically meaningful efficacy, with improvements in the Severity of Alopecia Tool score observed in patients with alopecia areata over a 3-year period, demonstrating long-term benefit in both clinician- and patient-reported outcomes.

This study observed that males with androgenetic alopecia using dutasteride showed significantly improved COVID-19 outcomes, including shorter duration of symptoms and viral shedding, compared to those not using it and non-AGA males.

This study found that for patients with moderate-to-severe chronic hand eczema, combining fractional CO2 laser with halometasone cream was more effective than using halometasone cream alone, with a higher treatment success rate and fewer relapses, though skin pigmentation was a common side effect.

This study found that a supplement containing cystine, B vitamins, and minerals improved hair condition in 34 women with diffuse hair loss over six months, as evidenced by an increased anagen/telogen hair ratio, positive participant feedback, and no serious side effects.

This study found that both buffy coat and apheresis PRP are effective for treating androgenetic alopecia, with buffy coat PRP associated with higher patient-reported improvement despite lower platelet counts.

This study suggests that a proprietary nutraceutical supplement gummy and peptide serum regimen may be safe and effective for improving hair growth and density in females with pattern hair loss.

This clinical study found that using a cream or lotion as an additional treatment alongside standard care for atopic dermatitis significantly reduced symptoms and improved skin moisturization and barrier function within 28 days compared to standard care alone in participants with mild-to-moderate eczema.

This study found that a hair serum containing Acanthus ebracteatus extract improved hair regrowth in men with androgenic alopecia, increasing hair count and density of anagen hairs over a 6-month period, with combination treatments showing early effectiveness.

This study found that a combination of topical and oral treatment led to greater improvements in hair density, thickness, and anagen/telogen ratio in patients with androgenetic alopecia compared to topical treatment alone, with significant benefits observed over a 3-month period.

This study reports no new findings but provides corrected figures for the long-term safety and efficacy of ritlecitinib in treating alopecia areata from the ALLEGRO-LT phase 3 study.

This study found that women with PCOS exhibited higher levels of depression, tension induction, and impaired stress coping strategies compared to healthy controls, with these psychological issues correlating with hyperandrogenism but not with central obesity or insulin resistance.

This study found that a food supplement improved skin moisturization, elasticity, and thickness, reduced telogen hair density, and enhanced nail status in women with mild-to-moderate aging signs after 84 days.

This study found that SULT1A1 enzyme activity, crucial for activating minoxidil, is significantly lower in eyebrow and eyelash follicles compared to scalp follicles, suggesting that additional sulfotransferase supplementation might enhance minoxidil-based hair growth treatments for these areas.

In this case report, proliferative, lymphocytic, infundibular mural folliculitis and dermatitis have been documented in a female Labrador retriever in a location outside North America for the first time, detailing the dog's clinical symptoms, histopathological findings, and treatment.

This study found that Dr. SKS Hair Booster Serum significantly improved hair shaft diameter, terminal hair counts, and hair growth rate in women with PCOS experiencing female pattern hair loss, without any reported adverse events, over a six-month treatment period.

This study is investigating the efficacy and safety of proxalutamide, an androgen receptor antagonist, in treating severe or critically ill patients with COVID-19, aiming to provide new insights into potential therapeutic options. Results are not reported yet.

This study found that a combination of topical 5% minoxidil and 0.25% finasteride was more effective at improving hair density and satisfaction in men with androgenetic alopecia than either treatment alone over 24 weeks.